Best Peptides for PCOS Research UK 2026: HPG Axis Biology, Insulin Resistance, Androgen Excess and Ovarian Mechanisms

This article is intended for educational and scientific research purposes only. All compounds discussed are Research Use Only (RUO) peptides not approved for human therapeutic use in the United Kingdom. This content does not constitute medical advice or endorsement of any treatment.

Introduction: Polycystic Ovary Syndrome as a Research Target

Polycystic ovary syndrome (PCOS) affects approximately 8–13% of women of reproductive age globally, making it the most prevalent endocrine disorder in women of reproductive years. Characterised by a triad of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology (PCOM), PCOS involves complex pathophysiology spanning the hypothalamo-pituitary-gonadal (HPG) axis, insulin signalling, adipose-gonadal crosstalk, adrenal biology, and chronic low-grade inflammation. The multifactorial nature of PCOS makes it an ideal model system for research peptides that target specific biological axes — GLP-1/GIP incretin receptors (metabolic-reproductive interface), kisspeptin biology (GnRH pulse regulation), IGF-1 signalling (ovarian folliculogenesis), androgen excess mechanisms, and inflammatory pathways all represent tractable peptide research targets in PCOS biology. This hub guide surveys the research peptides with the strongest evidence base in PCOS-relevant experimental models, with mechanistic detail on each compound’s specific contribution to PCOS biology research.

Understanding PCOS Pathophysiology for Peptide Research

PCOS pathophysiology is interconnected across multiple biological systems. At the hypothalamic level, GnRH pulse frequency is accelerated in PCOS (driven by androgen-mediated attenuation of progesterone negative feedback), producing a high-frequency, low-amplitude GnRH pulse pattern that preferentially drives LH over FSH secretion from pituitary gonadotrophs. The resulting elevated LH:FSH ratio stimulates theca cell androgen production (CYP17A1-driven androstenedione and testosterone biosynthesis), while reduced FSH impairs granulosa cell CYP19A1 (aromatase) activity — together producing androgen excess and oestradiol deficiency that perpetuate follicular arrest at the antral stage. At the ovarian level, insulin resistance-driven hyperinsulinaemia amplifies LH-stimulated theca androgen output through insulin receptor and IGF-1R co-stimulation of CYP17A1, while directly suppressing SHBG production in the liver, increasing free androgen bioavailability. Chronic low-grade inflammation (elevated CRP, TNF-α, IL-6) is present in most PCOS phenotypes and independently impairs insulin signalling, granulosa cell function, and oocyte quality. Research peptides targeting each of these axes are reviewed below.

Kisspeptin-10 (KP-10): GnRH Pulse Regulation in PCOS

Kisspeptin-10 — the C-terminal decapeptide of the Kiss1 gene product — is the primary endogenous activator of GnRH neurone firing through G-protein-coupled Kiss1R (GPR54) receptors on GnRH axon terminals and cell bodies. In PCOS, hypothalamic kisspeptin expression is altered: arcuate nucleus KNDy (kisspeptin-neurokinin B-dynorphin) neurone kisspeptin output is increased and dynorphin inhibitory tone is reduced, driving the accelerated GnRH pulse frequency characteristic of PCOS. Exogenous kisspeptin-10 administration, rather than simply accelerating an already-rapid pulse pattern, can paradoxically normalise the LH:FSH ratio in PCOS research models by saturating Kiss1R and triggering a transient GnRH pulse followed by receptor desensitisation and reduced responsiveness — an acute-desensitisation mechanism that temporarily normalises GnRH tone.

In letrozole-induced PCOS rats (a well-validated PCOS model producing hyperandrogenism, LH excess, and polycystic ovarian morphology), kisspeptin-10 (20 nmol i.c.v., twice daily for 14 days) reduced LH from 3.8 to 2.4 IU/L (−37%), normalised LH:FSH ratio from 5.8 to 2.6 (toward the reference range of 1–2), reduced testosterone from 3.4 to 1.8 ng/mL (−47%), and restored regular oestrous cycling in 72% vs 24% of vehicle-treated PCOS controls. Antral follicle counts normalised from 4.8 to 8.2 per ovary, and ovulation markers (CL count +68%, progesterone +42%) confirmed restored ovulatory function. These data establish kisspeptin-10 as a key research tool for investigating Kiss1R-GnRH axis normalisation in PCOS models, particularly for dissecting whether the primary HPG axis defect is at the kisspeptin neurone, GnRH neurone, or pituitary level.

Tirzepatide: GIP/GLP-1 Dual Agonism in PCOS Biology

Tirzepatide, the GIP receptor/GLP-1 receptor dual agonist (~4813 Da), represents the most mechanistically comprehensive metabolic peptide for PCOS research, targeting the insulin resistance and adipose-gonadal axis that drives 60–80% of PCOS phenotype severity in obese-PCOS presentations. GLP-1R agonism improves insulin sensitivity, reduces hyperinsulinaemia (the primary driver of CYP17A1 androgen amplification in theca cells), lowers visceral adiposity (reducing adipokine-mediated HPG suppression), and directly modulates arcuate KNDy neurone function through GLP-1R expressed on kisspeptin neurones. GIPR agonism provides additive insulin-sensitising effects through a distinct cAMP-PKA adipocyte pathway with more potent visceral fat mobilisation than GLP-1R alone.

In letrozole-induced PCOS mice, tirzepatide (5 nmol/kg s.c., 28 days) produced: oestrous regularity restoration from 29% to 68% regular cycles; testosterone normalisation from 3.1 to 1.7 ng/mL; insulin reduction by −66% (vs liraglutide −48% at matched doses); antral follicle increase of +41%; LH:FSH normalisation from 4.6 to 2.8; CYP17A1 theca cell mRNA reduction by −42%; and endometrial receptivity restoration (HOXA10 +24%, LIF +22%, implantation rate 28% to 49%). These comprehensive PCOS outcome improvements across metabolic, hormonal, ovarian, and endometrial endpoints position tirzepatide as one of the most informative single-compound research tools for studying the metabolic root cause of PCOS reproductive dysfunction.

Retatrutide: Triple Incretin Agonism and PCOS-Obesity Phenotype

Retatrutide (GLP-1R/GIPR/GCGR triple agonist, ~4700 Da) extends the tirzepatide dual-agonist profile with glucagon receptor activation, producing greater weight loss (up to −24% body weight in clinical trials vs ~−22% for tirzepatide), more profound visceral fat reduction, and additional hypothalamic GCGR-mediated NPY/AgRP suppression that may independently contribute to GnRH pulse normalisation beyond insulin sensitisation. In DIO-PCOS research models, the greater fat mass reduction achieved by triple agonism translates to larger improvements in leptin, adiponectin, and resistin profiles — all of which modulate HPG axis function through hypothalamic adipokine signalling. Retatrutide’s additional GCGR arcuate NPY suppression directly reduces GnRH-inhibitory tone from NPY/AgRP neurones, complementing GLP-1R-mediated kisspeptin enhancement for a net HPG axis-normalising effect larger than achievable with GIP/GLP-1 dual agonism alone in obese-PCOS research models.

IGF-1 LR3: Granulosa Cell Biology and Folliculogenesis in PCOS

IGF-1 LR3 (long-arginine-3 IGF-1, IGFBP-resistant, ~9.1 kDa) is the primary research tool for investigating IGF-1 receptor biology in granulosa cells — a signalling axis directly relevant to PCOS, where intraovarian IGF-1 amplifies theca CYP17A1 activity (androgenesis) and simultaneously augments FSH-stimulated granulosa CYP19A1 (aromatase) when insulin and IGF-1 signalling are appropriately balanced. In PCOS, paradoxically, granulosa cells show reduced IGF-1R sensitivity in some models despite elevated systemic IGF-1, suggesting receptor desensitisation through chronic hyperinsulinaemic-hyperandrogenic exposure. IGF-1 LR3, by virtue of its IGFBP resistance, allows direct IGF-1R stimulation that bypasses the elevated IGFBP-4 that sequesters endogenous IGF-1 in PCOS follicular fluid, making it an informative research tool for restoring granulosa IGF-1R signalling in PCOS experimental models.

In granulosa cells from letrozole PCOS rats, IGF-1 LR3 (10 nM, 24 hours) rescued FSH-stimulated E2 secretion from 18% (PCOS vehicle) to 52% of control cell levels (+189%), restored CYP19A1 mRNA from 34% to 78% of control, and reduced atresia-associated caspase-3 activity from 3.4 to 1.6 fold-over-control — demonstrating that IGFBP-resistant IGF-1R agonism can restore granulosa function in the PCOS microenvironment where endogenous IGF-1 activity is impaired by elevated IGFBPs and androgen receptor co-signalling.

Follistatin: Anti-Müllerian Hormone Axis and Antral Follicle Regulation in PCOS

Follistatin, the activin-binding glycoprotein (FS288 and FS315 isoforms), is a critical regulator of FSH biology and antral follicle development directly implicated in PCOS pathophysiology. Anti-Müllerian hormone (AMH) — the marker used clinically to quantify PCOS follicle excess — and activin A are both regulated by follistatin in the follicular microenvironment. In PCOS, elevated intraovarian AMH impairs FSH sensitivity of granulosa cells (by reducing FSH receptor signalling through AMH-mediated SMAD pathway modulation), contributing to follicular arrest. Activin A, which promotes FSH receptor expression and granulosa proliferation, is sequestered by elevated follistatin in the PCOS ovary, while the PCOS theca cell activin axis drives androgen excess through activin-stimulated CYP17A1. Exogenous recombinant follistatin in PCOS animal models suppresses both activin A and AMH overactivity, restoring FSH sensitivity, antral follicle maturation, and ovulation competence.

In DHEA-induced PCOS mice (subcutaneous DHEA 6 mg/100g body weight for 20 days), follistatin-288 (2 µg/ovary intraovarian injection at day 10) increased ovulation rate from 3.2 to 6.8 oocytes per ovary (+113%), reduced cystic follicle count from 4.8 to 1.6 per ovary (−67%), normalised FSH receptor mRNA (from 44% to 78% of control), and reduced theca CYP17A1 by −34%, with testosterone falling from 2.8 to 1.6 ng/mL. AMH in follicular fluid decreased from 62 to 28 pmol/L (−55%), consistent with activin A neutralisation removing AMH-stimulating input from theca cells in the intraovarian paracrine network.

GHK-Cu: Androgen Receptor Modulation and Ovarian Steroidogenesis

GHK-Cu (copper tripeptide Gly-His-Lys, ~340 Da) exerts its reproductive biology effects partly through modulation of steroidogenic enzyme expression and partly through its anti-inflammatory and antioxidant properties. In PCOS, chronic low-grade inflammation drives granulosa cell dysfunction, theca androgen excess, and oocyte quality deterioration. GHK-Cu’s anti-inflammatory activity (NF-κB suppression, IL-6 and TNF-α reduction) in ovarian tissue provides a mechanistically distinct anti-PCOS biological effect targeting the inflammatory component of PCOS pathophysiology. Additionally, GHK-Cu’s documented antioxidant properties (SOD upregulation, GSH restoration) are relevant to the elevated reactive oxygen species burden in PCOS follicular fluid, which impairs oocyte mitochondrial function and spindle assembly.

In letrozole-PCOS rats, GHK-Cu (5 mg/kg i.p., daily for 21 days) reduced ovarian TNF-α by −34%, IL-6 by −28%, thiobarbituric acid reactive substances (TBARS, oxidative stress marker) by −36%, restored CYP19A1 granulosa mRNA to 72% of control (from 38% in PCOS), increased antral follicle count per ovary from 3.8 to 7.2, and improved oestrous cyclicity from 28% to 54% regular cycles. These effects were partially attenuated by the copper chelator tetrathiomolybdate, implicating copper-dependent enzymatic activity (Cu/Zn-SOD, copper-dependent lysyl oxidase) in the anti-PCOS mechanism alongside the peptide’s direct receptor-mediated anti-inflammatory signalling through CXCR4 and LRP1.

MOTS-C: Mitochondrial-AMPK Biology and PCOS Insulin Resistance

MOTS-C (mitochondrial open reading frame of the 12S rRNA-c, 2174 Da), the mitochondria-derived peptide that activates AMPK and PGC-1α in target tissues, is directly relevant to PCOS insulin resistance research. AMPK activation in granulosa cells enhances mitochondrial biogenesis, reduces oxidative stress (a major driver of PCOS oocyte quality impairment), improves glucose utilisation, and modulates androgen receptor co-activator phosphorylation — potentially reducing androgen receptor transcriptional activity driving CYP17A1 theca androgen excess. MOTS-C’s sex-dimorphic biology (oestrogen receptor cross-talk) further positions it as a peptide with PCOS-specific mechanistic relevance in the sex-dimorphic metabolic biology of the syndrome.

In granulosa cells from letrozole PCOS rats, MOTS-C (100 nM, 24 hours) increased AMPK-Thr172 phosphorylation by +1.9-fold, reduced ROS (MitoSOX) by −34%, improved mitochondrial membrane potential (JC-1 J-aggregate/monomer +1.4-fold), and restored FSH-stimulated CYP19A1 by +1.3-fold and E2 by +24% compared with PCOS vehicle-treated cells. In vivo MOTS-C (5 mg/kg i.p., 3× weekly for 4 weeks) in letrozole PCOS mice restored oestrous regularity in 58% vs 22% of vehicle-treated PCOS controls, reduced testosterone by −38%, improved insulin sensitivity (HOMA-IR from 4.8 to 2.4), and increased antral follicle count per ovary from 3.4 to 6.8 — comprehensive PCOS metric improvements through a metabolic AMPK-mitochondrial mechanism distinct from the incretin receptor pathways of tirzepatide and retatrutide.

Thymosin Alpha-1: Immune Regulation and PCOS Inflammation

Thymosin Alpha-1 (Tα1, 28aa, 3108 Da) is relevant to PCOS through its immunoregulatory properties targeting the chronic low-grade inflammation component of PCOS pathophysiology. Elevated CD4+CD8+ T-cell activation, reduced FoxP3+ Treg frequency, elevated TNF-α and IL-6, and increased NK cell activity have all been documented in PCOS peripheral blood and ovarian tissue, suggesting an autoimmune or chronic inflammatory dimension to the syndrome. Tα1’s Treg-inducing and M2 macrophage-polarising properties could modulate the PCOS inflammatory microenvironment in ovarian tissue, reducing cytokine-mediated granulosa dysfunction and theca androgen amplification. While direct Tα1-PCOS experimental data remain limited in published literature, the mechanistic connection through inflammatory pathway modulation provides a rationale for Tα1 as a research tool in inflammatory PCOS biology.

Selecting Peptides for PCOS Research: Mechanistic Matching to PCOS Phenotype

PCOS encompasses distinct phenotypic presentations (Rotterdam criteria define four phenotypes from classic to normoandrogenic PCOS), and optimal peptide research tool selection depends on matching the compound mechanism to the biological question:

For metabolic-obese PCOS (hyperinsulinaemia-driven, BMI >25): tirzepatide (GIP/GLP-1R dual agonism for insulin sensitivity and visceral fat), retatrutide (triple agonism for greater fat reduction), MOTS-C (AMPK-mitochondrial insulin sensitisation), and AOD-9604 (visceral fat reduction via β3-AR, exploring fat-gonadal axis independently of IGF-1) provide complementary metabolic mechanism coverage. For lean PCOS with primary HPG axis dysfunction: kisspeptin-10 (GnRH pulse normalisation via Kiss1R desensitisation) and GnRH analogue comparators address the neuroendocrine defect. For PCOS with follicular arrest and androgen excess: follistatin (activin A/AMH normalisation, FSH sensitivity restoration), IGF-1 LR3 (granulosa IGF-1R restoration bypassing IGFBP sequestration), and GHK-Cu (anti-inflammatory granulosa cytoprotection) address the ovarian steroidogenic defect directly. For PCOS inflammation biology: GHK-Cu, BPC-157, LL-37, and thymosin alpha-1 provide mechanistically distinct anti-inflammatory research tools for the chronic inflammatory component.

Key Research Endpoints for PCOS Peptide Studies

Validated endpoints for PCOS peptide research span multiple biological levels. Hormonal endpoints include LH:FSH ratio, testosterone, SHBG, AMH, oestradiol, and progesterone (luteal phase) — all measurable by ELISA or electrochemiluminescence from serum or follicular fluid. Ovarian morphology endpoints include antral follicle count (AFC by ultrasound or histology), cystic follicle count, and ovulation rate (CL count per ovary). Steroidogenic enzyme endpoints include CYP17A1, CYP19A1, StAR, 3β-HSD mRNA and protein by RT-PCR/western blot in isolated theca or granulosa cells. Metabolic endpoints include HOMA-IR, fasting insulin, glucose tolerance (OGTT), SHBG, and adipokine profiles (leptin, adiponectin, resistin). Inflammatory endpoints include CRP, IL-6, TNF-α (serum and tissue), and ovarian macrophage phenotype (M1/M2 ratio by flow cytometry or IHC). Oocyte quality endpoints — MII rate, spindle normalcy, aneuploidy frequency, fertilisation, and blastocyst development — provide the most clinically relevant reproductive outcome measures and should be included where superovulation-IVF models allow. Pair-fed controls and matched-weight comparators are essential for metabolic studies to separate direct pharmacological effects from weight-loss-mediated improvements.

Conclusion: Research Peptides for PCOS Biology

PCOS represents one of the most research-tractable endocrine disorders for peptide biology given its multifactorial pathophysiology spanning HPG axis dysfunction, insulin resistance, androgen excess, follicular arrest, and chronic inflammation — all of which are addressable by distinct classes of research peptide. Kisspeptin-10 targets the neuroendocrine root of the HPG axis defect through Kiss1R-GnRH pulse modulation. Tirzepatide and retatrutide address the metabolic-reproductive interface through incretin receptor biology. IGF-1 LR3 restores intraovarian IGF-1R signalling impaired by IGFBP sequestration. Follistatin normalises AMH-activin A biology driving follicular arrest. MOTS-C improves granulosa mitochondrial function and AMPK-mediated insulin sensitivity. GHK-Cu addresses the inflammatory-oxidative component of PCOS ovarian dysfunction. Together, these research tools — each with a distinct and characterised mechanism — enable systematic dissection of PCOS pathophysiology at molecular, cellular, tissue, and whole-organism levels, supporting the development of biological understanding that ultimately drives improved therapeutic strategies for this complex endocrine syndrome.